WO2012061239A3 - Novel vaccines against pandemic influenza virus a/h1n1 - Google Patents

Novel vaccines against pandemic influenza virus a/h1n1 Download PDF

Info

Publication number
WO2012061239A3
WO2012061239A3 PCT/US2011/058336 US2011058336W WO2012061239A3 WO 2012061239 A3 WO2012061239 A3 WO 2012061239A3 US 2011058336 W US2011058336 W US 2011058336W WO 2012061239 A3 WO2012061239 A3 WO 2012061239A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza virus
vaccines against
pandemic influenza
novel vaccines
against pandemic
Prior art date
Application number
PCT/US2011/058336
Other languages
French (fr)
Other versions
WO2012061239A2 (en
Inventor
Hector Zepeda
Octavio Garcia
Original Assignee
Opko Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Pharmaceuticals, Llc filed Critical Opko Pharmaceuticals, Llc
Priority to MX2013004975A priority Critical patent/MX2013004975A/en
Publication of WO2012061239A2 publication Critical patent/WO2012061239A2/en
Publication of WO2012061239A3 publication Critical patent/WO2012061239A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to influenza virus vaccines, and in particular to an influenza virus which has at least its hemagglutinin gene comprising a D222 mutation, and an oseltamivir resistant neuraminidase gene. In some embodiments the influenza virus vaccine further comprises a matrix protein comprising a mutation that increases specific immune response in humans. The virus is useful for production of vaccines against hypervirulent and oseltamivir-resistant influenza.
PCT/US2011/058336 2010-11-02 2011-10-28 Novel vaccines against pandemic influenza virus a/h1n1 WO2012061239A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2013004975A MX2013004975A (en) 2010-11-02 2011-10-28 Novel vaccines against pandemic influenza virus a/h1n1.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40930310P 2010-11-02 2010-11-02
US61/409,303 2010-11-02

Publications (2)

Publication Number Publication Date
WO2012061239A2 WO2012061239A2 (en) 2012-05-10
WO2012061239A3 true WO2012061239A3 (en) 2012-06-28

Family

ID=46025035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/058336 WO2012061239A2 (en) 2010-11-02 2011-10-28 Novel vaccines against pandemic influenza virus a/h1n1

Country Status (3)

Country Link
MX (1) MX2013004975A (en)
TW (1) TWI620819B (en)
WO (1) WO2012061239A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130140050A (en) * 2010-11-02 2013-12-23 헥토 마뉴엘 제페다 로페즈 Novel vaccines against the a/h1n1 pandemic flu virus
US10022434B2 (en) 2013-03-15 2018-07-17 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175909A1 (en) * 2004-05-25 2009-07-09 Medimmune, Llc Influenza Hemagglutinin And Neuraminidase Variants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175909A1 (en) * 2004-05-25 2009-07-09 Medimmune, Llc Influenza Hemagglutinin And Neuraminidase Variants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 22 April 2010 (2010-04-22), STARICK. ET AL.: "Influenza A virus (A/Germany- BY/74/2009(H1N1)) segment 4 hemagglutinin (HA) gene, complete cds.", retrieved from http://www.ncbi.nlm.nih.gov/protein/ADF58349 accession no. M138501. *
DATABASE GENBANK 23 April 2010 (2010-04-23), retrieved from http://www.ncbi.nlm.nih.gov/nuccore/GU571155 accession no. U571155. *
MEMOLI ET AL.: "Rapid Selection of Oseltamivirand Peramivir-Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised Hosts.", CLIN INFECT DIS., vol. 50, no. 9, 1 May 2010 (2010-05-01), pages 1252 - 1255, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/nuccore/GU571155> *
POTDAR ET AL.: "Genetic Characterization of the Influenza A Pandemic (H1N1) 2009 Virus Isolates from India.", PLOS ONE, vol. 5, no. 3, 15 March 2010 (2010-03-15), pages E9693 *

Also Published As

Publication number Publication date
WO2012061239A2 (en) 2012-05-10
TWI620819B (en) 2018-04-11
MX2013004975A (en) 2014-01-17
TW201249996A (en) 2012-12-16

Similar Documents

Publication Publication Date Title
WO2010077986A3 (en) Production of influenza vaccines
WO2012060678A3 (en) Novel vaccines against the a/h1n1 pandemic flu virus
NZ627796A (en) Influenza virus vaccines and uses thereof
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
PH12015501482A1 (en) Nasal influenza vaccine composition
WO2011094358A9 (en) Influenza nucleic acid molecules and vaccines made therefrom
IL231547B (en) A chimeric influenza virus hemagglutinin (ha) polypeptide,an immunogenic composition comprising same and uses thereof
WO2013044203A3 (en) Novel influenza hemagglutinin protein-based vaccines
EA201290897A1 (en) VACCINES FOR PANDEMIC FLU
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses h3n2h2n2 b
AU2011280259A8 (en) Influenza vaccine
WO2013043067A3 (en) Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine
Robertson et al. Prospects for controlling future pandemics of influenza
WO2012082803A3 (en) Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof
MX363464B (en) Influenza h5 vaccines.
WO2012061239A3 (en) Novel vaccines against pandemic influenza virus a/h1n1
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
MX343411B (en) Influenza hemagglutinin and neuraminidase variants.
FR2962739B1 (en) MODIFIED VIRAL STRAINS AND METHOD FOR IMPROVING VACCINE SEED PRODUCTION OF INFLUENZA VIRUSES
EP2636735A4 (en) Recombinant vaccinia virus having hemagglutinin protein genes derived from novel influenza viruses
SG10201601365RA (en) Fragments of the pa subunit of rna dependent rna polymerase from pandemic influenza virus a 2009 h1n1, and their use
MX2011011561A (en) Novel vaccines against the a/h1n1 pandemic flu virus.
WO2011138032A3 (en) Universal influenza vaccines and methods for their generation
EP2195019A4 (en) Method of eliciting an immune response against pandemic influenza virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11838587

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/004975

Country of ref document: MX

122 Ep: pct application non-entry in european phase

Ref document number: 11838587

Country of ref document: EP

Kind code of ref document: A2